Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies Appoints James McGorry to Board of Directors

Jan 7, 2014

January 7, 2014 (St. Louis, MO) – ISTO Technologies, Inc., a privately-held orthobiological regenerative medicine company, announced today that James McGorry, a seasoned executive with deep healthcare industry experience, has been appointed to its Board of Directors.

“We welcome Jim McGorry, whose expertise in the biotech industry and leadership experience with ground-breaking oncological and transplant therapies will help guide ISTO as we continue to develop and promote our portfolio of cell-based cartilage products,” said Mitchell Seyedin, Ph.D., the Company’s President and Chief Executive Officer.

Mr. McGorry is Executive Vice President and General Manager of the Translational Oncology Solutions for Champions Oncology, a personalized medicine company whose technology determines the optimal therapies for individual specific cancer tumor types.  He previously was Executive Vice President at Accellent, a provider of outsourced manufacturing services to the medical device industry. Prior to that, he spent 12 years with Genzyme, ultimately as Senior Vice President of Oncology and Transplant, responsible for establishing and executing the commercial development, product general management and global expansion of Genzyme’s Oncology franchise in 90 countries.  Jim previously spent over ten years with Baxter Healthcare and its predecessor, American Hospital Supply in various sales and commercial roles including Vice President of Corporate Sales, Southern Region, where he negotiated and implemented a creative risk-sharing partnership with Duke Medical Center.

Mr. McGorry graduated from the United States Military Academy at West Point with a Bachelor of Science in Engineering, and served in the United States Military from 1979 to 1985. He holds an M.B.A. degree from the Fuqua School of Business at Duke University. Mr. McGorry also serves on the board of directors of Harvard Apparatus Regenerative Medicine (HART), a public company focused on regenerative organs for transplant.

About ISTO Technologies, Inc.
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications.  ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone.  The Company’s proprietary cell-based orthobiologic platform harnesses the high regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue.   In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 28,000 surgeries at U.S. hospitals to date.

To top